Charlotte's Web (CWBHF) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Apr, 2026Executive summary
A $10 million equity investment by BT DE Investments Inc. (BAT) will be made at a minimum price of C$0.94 per share, with a maximum of 14,760,638 shares to be issued, expected to close around May 28, 2026.
Concurrently, BAT will convert a C$75.3 million convertible debenture into 95,281,277 common shares at C$0.94 per share, raising BAT's ownership to approximately 40.8% of the company on a non-diluted basis.
The total equity commitment from BAT, including the new investment and debenture conversion, is approximately C$103 million (US$75 million).
The proceeds are earmarked to support participation in the CMS Innovation Center program, or, if that does not proceed, to sustain medical channels or other operational needs, but not for dividends, buybacks, or extraordinary compensation.
Voting matters and shareholder proposals
Shareholder approval is required for the investment and related transactions, with a special meeting to be held within 70 days of the agreement.
The board will recommend shareholders vote in favor of the resolutions, and a proxy statement will be filed with the SEC.
Board of directors and corporate governance
BAT will have the right to nominate directors proportional to its equity ownership, with a minimum of two nominees as long as it holds at least 10% of the company.
BAT's nomination rights terminate if its ownership falls below 10%.
BAT will have board observer rights and representation on board committees, subject to independence and expertise requirements.
Latest events from Charlotte's Web
- Returned to growth as the #1 CBD brand, leveraging innovation, partnerships, and regulatory momentum.CWBHF
Investor presentation26 Apr 2026 - Shareholders to vote on BAT transaction, director elections, and key governance matters.CWBHF
Proxy filing16 Apr 2026 - Key votes include director elections and a debenture amendment that may shift company control.CWBHF
Proxy filing16 Apr 2026 - Shareholders to vote on BAT's conversion to a control person, reshaping ownership and governance.CWBHF
Proxy filing6 Apr 2026 - Debt eliminated, revenue up, and new capital positions for Medicare-driven growth.CWBHF
Q4 202531 Mar 2026 - BAT transaction and regulatory momentum drive financial and strategic transformation.CWBHF
Proxy filing31 Mar 2026 - BAT's conversion and $10M investment will eliminate $65M debt and give it 40% ownership.CWBHF
Proxy filing31 Mar 2026 - Sequential revenue growth and cost cuts support breakeven and turnaround progress.CWBHF
Q2 20242 Feb 2026 - Cost discipline, new channels, and product innovation drive improved Q4 results.CWBHF
Q4 202424 Dec 2025